RGBP (Regen BioPharma) Net Margin %: 1,681.36% (As of Mar. 2026)


What is Regen BioPharma Net Margin %?

Regen BioPharma RGBP +33.33% Net Margin % is 1,681.36% as of Mar. 2026. The stock has 7 warning signs investors should review. Among 946 Biotechnology companies, Regen BioPharma ranks worse than 65.22% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Regen BioPharma's Net Income for the three months ended in Mar. 2026 was $0.99 Mil. Regen BioPharma's Revenue for the three months ended in Mar. 2026 was $0.06 Mil. Therefore, Regen BioPharma's net margin for the quarter that ended in Mar. 2026 was 1,681.36%.

The historical rank and industry rank for Regen BioPharma's Net Margin % or its related term are showing as below:

RGBP' s Net Margin % Range Over the Past 10 Years
Min: -5308.18   Med: -1461.26   Max: 2483.64
Current: -302.97

RGBP's Net Margin % is ranked worse than
65.22% of 946 companies
in the Biotechnology industry
Industry Median: -88.815 vs RGBP: -302.97

Regen BioPharma  (OTCPK:RGBP) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Regen BioPharma Net Margin % Related Terms

Regen BioPharma Net Margin % Historical Data

* Premium members only.

The historical data trend for Regen BioPharma's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regen BioPharma Net Margin % Chart

Regen BioPharma Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3,956.14 943.64 432.07 -281.86 -537.97

Regen BioPharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -32.20 -283.05 -969.49 -1,640.68 1,681.36

RGBP vs ENDV, ADTX, SCPX: Net Margin % Comparison

For the Biotechnology subindustry, Regen BioPharma's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regen BioPharma Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regen BioPharma's Net Margin % distribution charts can be found below:

* The bar in red indicates where Regen BioPharma's Net Margin % falls into.


Regen BioPharma Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Regen BioPharma's Net Margin for the fiscal year that ended in Sep. 2025 is calculated as

Net Margin=Net Income (A: Sep. 2025 )/Revenue (A: Sep. 2025 )
=-1.275/0.237
=-537.97 %

Regen BioPharma's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=0.992/0.059
=1,681.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 1,681.36% mean?
Regen BioPharma (RGBP) has a Net Margin % of 1,681.36% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Regen BioPharma and its competitors. According to the industry distribution chart, Regen BioPharma ranks #617 out of 946 companies in the Biotechnology industry, placing it in the top 65.2%.
Is Regen BioPharma's Net Margin % too high?
Regen BioPharma's current Net Margin % is 1,681.36%. Based on the distribution chart, Regen BioPharma ranks #617 out of 946 companies in the Biotechnology industry, which is below the industry midpoint.
How does Regen BioPharma's Net Margin % compare to ENDV and ADTX?
According to the Biotechnology industry distribution chart, Regen BioPharma ranks #617 out of 946 companies for Net Margin %. This places Regen BioPharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Regen BioPharma and its competitors. Regen BioPharma's current Net Margin % is 1,681.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regen BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Regen BioPharma (RGBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.02, compared to a current price of $0.00 — trading 99% below its estimated fair value. The current Net Margin % is 1,681.36%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Regen BioPharma (RGBP), the current Net Margin % is 1,681.36% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regen BioPharma Business Description

Other Exchanges RGBPP.PFD:USA
Address 8697 La Mesa Boulevard, Suite C, La Mesa, CA, USA, 91942
Regen BioPharma Inc is a USA-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II are cellular therapies designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.